Work

A Phase I Trial of PD 0332991, a Novel, Orally-Bioavailable CDK4/6-Specific Inhibitor Administered in Combination with Bortezomib and Dexamethasone to Patients with Relapsed and Refractory Multiple Myeloma.

Year: 2009

Type: article

Source: Blood

DOI: 10.1182/blood.v114.22.1877.1877

Authors: Ruben Niesvizky, Scott Ely, David S Jayabalan, Megan C. Manco, Seema Singhal, Mary Crann, Rachel Courtney, Cynthia DuFresne, Keith D. Wilner, Isan Chen, Tomer Mark, John P. Leonard, Morton Coleman, Maurizio DiLiberto, Xiangao Huang, Selina Chen-Kiang

Institutions: Cornell University, Weill Cornell Medicine, NewYork–Presbyterian Hospital, Northwestern University, Pfizer (United States)

Language: English

Topic: Multiple Myeloma Research and Treatments

Subfield: Hematology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2559951930

FWCI: 0.877

Cites:

Cited by: 6

Related to: 10